News Digest / Ticker:SNY

Ticker:SNY

06:45am, Friday, Jan 16, 2026

UBS Cuts Sanofi to Neutral Amid Pipeline Setbacks and Dupixent Patent Concerns

UBS downgrades Sanofi to neutral, slashing earnings forecasts after trial failures and risks to key drug Dupixent. Weak pipeline and FDA delays cloud the pharma giant's growth outlook.

04:15am, Friday, Jul 25, 2025

Sanofi's Sarclisa Scores EU Nod for Frontline Multiple Myeloma, Boosting Potential Market Reach

10:03am, Monday, Jun 02, 2025

Sanofi Strengthens Biotech Ties with Nurix Therapeutics: A $465 Million Opportunity Unfolds

04:04am, Thursday, Mar 20, 2025

Sanofi Eyes Expansion with $600 Million Acquisition of Dren Bio's Autoimmune Treatment: What Traders Need to Know

08:17am, Friday, May 10, 2024

Key Insights Before Friday's Stock Market Opening Bell